# Expert Drug Development Analysis: Astrocytic TNT Formation Targets
## Executive Assessment
The skeptic's critique is largely correct: several hypotheses cite literature that doesn't directly support their claims, and the fundamental premise—that TRIM46 must be involved in astrocytic TNTs—remains unproven. However, the framework addresses a legitimate biological question: what molecular machinery drives astrocytic intercellular communication via TNTs?
From a drug development perspective, I need to reframe these hypotheses around **druggable targets** with **existing chemical matter** and **clear path to intervention**.
---
## Druggability Analysis by Hypothesis
### Hypothesis 3 (Revised): P2X7R-PKCα-VASP Axis
**Recommended Focus**
| Component | Druggability | Chemical Matter | Clinical Status |
|-----------|--------------|-----------------|-----------------|
| P2X7R | **HIGH** - Ion channel, multiple antagonist chemotypes | AZD9056, JNJ-54175446, CE-224,535 | Phase I-II completed |
| PKCα | **MODERATE** - Kinase with ATP-binding pocket | Sotrastaurin (AEB071), ruboxistaurin | Clinical candidates exist |
| VASP | **LOW** - Protein-protein interaction surface | No direct inhibitors | Research tool only |
**Tool Compounds and Clinical Candidates:**
1. **P2X7R Antagonists:**
- **AZD9056** (AstraZeneca): Phase IIb for rheumatoid arthritis; favorable safety profile; blood-brain barrier penetration questionable
- **JNJ-54175446** (Janssen): Phase I completed; CNS penetration being evaluated
- **BTC-1** (Biohaven): Preclinical, CNS-penetrant
- **CE-224,535** (Pfizer): Phase II completed for RA
2. **PKCα Inhibitors:**
- **Sotrastaurin**: Broad PKC inhibitor (IC50 ~2.5 nM for PKCθ), used in transplantation trials; limited CNS penetration
- **GF-109203X**: Research tool, non-selective PKC inhibitor
**Critical Correction to Original Hypothesis:**
The skeptic correctly identifies that VASP Ser157 is phosphorylated by PKA, not PKCα. VASP is phosphorylated at:
- **Ser157**: PKA (cAMP-dependent)
- **Ser239**: PKG (cGMP-dependent)
- **Thr278**: PKC (shown in platelets, PMID: 11572937)
If pursuing this hypothesis, focus on VASP Thr278 or use phospho-antibodies that distinguish sites.
**Safety Concerns:**
- P2X7R knockout mice are viable with minimal phenotypes (immunological abnormalities only)
- Pan-PKC inhibition causes metabolic and GI toxicity
- Need isoform-selective PKCα inhibitors
**Revised Confidence: 0.40**
---
### Hypothesis 2 (Revised): Myosin X as P2X7-PKCα Effector
**Highest Confidence Target**
The skeptic correctly points to Myo10 (Myosin X) as directly implicated in astrocytic TNT formation (PMID: 30115665). This is a more parsimonious explanation than VASP.
| Aspect | Assessment |
|--------|------------|
| Target | Myosin X (MYO10) - motor protein |
| Druggability | **MODERATE** - Motor proteins are challenging but not impossible |
| Chemical Matter | **Limited** - No selective Myo10 inhibitors; Blebbistatin inhibits Myosin II primarily |
| Research Tools | Myo10 siRNA, CRISPR constructs available |
| Clinical Candidates | None |
**Validation Required:**
- Confirm Myo10 phosphorylation by PKCα in astrocytes
- Demonstrate Myo10 localization to TNTs by super-resolution microscopy
- Test whether Myo10 knockdown abolishes P2X7-mediated TNT formation
**If Validated - Drug Development Path:**
1. Develop Myo10 motor domain inhibitors (high-risk)
2. Target upstream PKCα more selectively
3. Identify downstream effectors for better drug targets
---
### Hypothesis 1 (Revised): NF-κB/STAT3 for Neuroinflammatory Context
**Indirect Approach with Established Compounds**
If astrocytic TRIM46 is only expressed pathologically, targeting its induction has different implications:
| Target | Druggability | Clinical Candidates |
|--------|--------------|---------------------|
| NF-κB pathway | Moderate - indirect approaches | **Dimethyl fumarate** (Tecfidera) - approved for MS |
| STAT3 | Low-moderate - transcription factor | **Tofacitinib**, ruxolitinib (JAK inhibitors reduce STAT3 signaling) |
| TRIM46 expression | Not druggable directly | N/A |
**Existing Approved Drugs:**
- **Dimethyl fumarate**: Activates Nrf2, modulates NF-κB; approved for multiple sclerosis; astrocytic effects documented
- **Teriflunomide**: Inhibits dihydroorotate dehydrogenase; affects pyrimidine synthesis
- **Fingolimod**: S1P receptor modulator; keeps lymphocytes in lymph nodes
**Problem:** These drugs have broad mechanisms and wouldn't selectively affect TRIM46 even if it were induced.
---
## Competitive Landscape
### Companies with CNS-Relevant P2X7 Programs:
| Company | Compound | Indication | Status |
|---------|----------|------------|--------|
| AstraZeneca | AZD9056 | RA, COPD | Discontinued post-Phase II |
| Janssen | JNJ-54175446 | Major depression | Phase I |
| Biohaven | BHV-5500 series | ALS, neuroprotection | Preclinical |
| Roche/Genentech | GNE-349 | Inflammatory diseases | Preclinical |
| Pfizer | CE-224,535 | RA | Discontinued |
**Market Opportunity:**
No P2X7 antagonists are approved. The failure of AZD9056 in RA trials suggests efficacy may be context-dependent. Neuroinflammatory indications (MS, ALS, Alzheimer's) remain open.
### Strategic Consideration:
If the mechanism is astrocytic TNT formation for neuroprotection, P2X7 antagonists might actually be **counterproductive**—they could block beneficial intercellular communication. Consider whether TNT formation is:
- **Adaptive**: Neuroprotective material transfer (argument for agonists)
- **Pathological**: Spreading of toxic aggregates in neurodegeneration (argument for antagonists)
---
## Revised Experimental Priorities
### Tier 1: Establish Baseline Truth (6-12 months, ~$150K)
**Essential experiments before drug development:**
1. **Single-cell RNA-seq of purified astrocytes**
- Confirm TRIM46 expression (or absence) in primary mouse/human astrocytes
- Use MACS or FACS with ACSA-2 (astrocyte marker)
- Control for neuronal contamination with TuJ1/Nefh staining
- **Cost**: ~$5,000-10,000 per condition
2. **TRIM46 CRISPR knockout in astrocytes**
- Purchase or generate Trimm46 flox/flox mice (available from JAX: C57BL/6J)
- Cross with GFAP-Cre or Aldh1l1-CreERT2 for astrocyte-specific deletion
- **Cost**: $10,000-20,000 for targeting vector; 6-9 months for generation
3. **TNT formation assay in TRIM46-null astrocytes**
- Use the established CFSE/H2B-RFP co-culture system
- Quantify TNT frequency and functionality (FRET calcium signaling)
- **Cost**: ~$2,000 per experiment
### Tier 2: Identify True Effector Pathways (12-24 months, ~$500K)
**If TRIM46 is NOT expressed in astrocytes:**
4. **Phosphoproteomics screen for PKCα substrates during TNT formation**
- Stimulate astrocytes with P2X7 agonist (BzATP) or mechanical stress
- SILAC or TMT labeling + anti-phosphoSer/Thr IP + mass spectrometry
- **Expected outputs**: List of 50-200 phosphoproteins
- **Cost**: $30,000-50,000 per condition
5. **Validate top candidates from phosphoproteomics:**
- Myosin X (Myo10) - antibody available (Proteintech #27734)
- ERM proteins (ezrin, radixin, moesin)
- MARCKS/MARCKSL1
- **Cost**: $5,000 per antibody validation
6. **CRISPR screen for TNT regulators**
- GeCKO or Brunello library targeting kinome/phosphatome
- Score for TNT formation phenotype
- **Cost**: $50,000-100,000 including sequencing
### Tier 3: Target Validation and Chemical Matter (24-36 months, ~$1-2M)
**If specific target is validated:**
7. **Develop or identify selective inhibitors:**
- For kinases: Test known inhibitors from pharmaceutical partners
- For Myo10: Develop motor domain assay for HTS
- For channels: Use existing P2X7 antagonists
8. **Efficacy studies in disease models:**
- Alzheimer's: 5xFAD or APP/PS1 mice
- ALS: SOD1 G93A mice
- MS/EAE: Myelin oligodendrocyte glycoprotein (MOG) immunization
- **Cost**: $100,000-300,000 per model
---
## Practical Recommendations
### For Drug Development Programs:
| Option | Rationale | Risk Level | Timeline |
|--------|-----------|------------|----------|
| **Partner with P2X7 program** | Repurpose existing antagonists | Low | 1-2 years |
| **Acquire Myo10 IP** | Novel mechanism, high risk/reward | High | 3-5 years |
| **Focus on upstream STAT3/NF-κB** | Approved drugs exist | Low-moderate | 1-2 years |
| **Diagnostic rather than therapeutic** | Develop TRIM46 as biomarker | Low | 6-12 months |
### Most Defensible Near-Term Strategy:
**Reposition existing P2X7 antagonists** for TNT-mediated neuroprotection:
- Negotiate licensing for AZD9056 or JNJ-54175446
- Run Phase II in Alzheimer's with TNT biomarkers as secondary endpoint
- Demonstrate that P2X7 blockade preserves intercellular astrocyte communication
- **Risk**: P2X7 antagonists may actually impair beneficial TNTs
**Alternatively, screen for P2X7 agonists** that enhance TNT formation for neuroprotection:
- No approved agonists exist
- Allosteric modulators may achieve this
- Higher development risk
---
## Summary
| Hypothesis | Drug Development Potential | Timeline to IND | Key Barrier |
|------------|---------------------------|-----------------|-------------|
| 3 (P2X7-VASP) | **Moderate** - Good target, some correction needed | 3-4 years | VASP pharmacology unclear |
| 3 (Myo10) | **High potential** - Direct link to TNTs | 5-7 years | No chemical matter |
| 1 (NF-κB/STAT3) | **Low** - Too indirect | 1-2 years | Non-specific |
| 2 (MAP1B) | **Very Low** - Not druggable | N/A | Wrong target |
| 4-7 | **Speculative** - Require validation first | >5 years | Multiple unknowns |
**Bottom Line:** The field should first establish whether TRIM46 is relevant to astrocytic TNTs at all (cost: ~$200K, 12 months). If yes, determine whether P2X7 antagonists help or harm TNT formation. If TRIM46 is a dead end, Myo10 is the most promising alternative with direct experimental support.